Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Partners with Leading US HIFU provider, Vituro Health Adds Ablatherm Robotic HIFU
  Dr. S. Scionti , Medical Director of Vituro and most experienced HIFU urologist in the U.S. to start treating with Ablatherm in September LYON, France , August 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company signed a partnership
View HTML
Toggle Summary EDAP TMS to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
LYON, France , August 24, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski , Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017
View HTML
Toggle Summary EDAP TMS Reports Record Second Quarter and First Half 2017 Results
EDAP-TMS Reports Record Second Quarter and First Half 2017 Results Revenue increased 13.7% to a record €9.3 million for the second quarter of 2017 compared to €8.2 million in 2016 HIFU revenue grew 25% when compared to first quarter of 2017 Ablatherm Fusion 510(k) submission completed C-Code
View HTML
Toggle Summary EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017
PRESS RELEASE Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Rich Cockrell CG CAPITAL 877.889.1972 rich@cg.capital   EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017 Conference Call
View HTML
Toggle Summary EDAP Announces filing of 510(k) Application for Ablatherm-Fusion® device
LYON, France , July 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a 510(k) application for its Ablatherm Fusion device, enabling a more precise method for targeting of diagnosed areas within the prostate.
View HTML
Toggle Summary EDAP to Host Webcast Discussing HIFU Devices with an American Key Opinion Leader
Webcast to be held Thursday, July 27 th , 2017 LYON, France , July 18, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company plans to host an investor call with commentary from an American robotic surgeon and oncologist to
View HTML
Toggle Summary EDAP Announces Withdrawal of 510(k) Application for Focal One® to be Followed by New Submission to Conform to FDA Review Rules
  New 510(k) With New Clinical Data to be Submitted for Focal One® Initial 510(k) to be submitted for Ablatherm Fusion® LYON, France , July 17, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company has withdrawn the 510(k)
View HTML
Toggle Summary EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate
Billing code will take effect July 1st, 2017 LYON, France , May 22, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the Centers for Medicare and Medicaid Services (CMS) have established a new billing code for HIFU ablation of
View HTML
Toggle Summary EDAP TMS SA Reports First Quarter 2017 Results
Total revenue of EUR 8.7 million ( USD 9.3 million ) for Q1 2017  +16.5% growth in HIFU treatment driven recurring revenues Strong cash position of EUR 20.3 million ( USD 21.7 million ) as of March 31, 2017 CMS Medicare C-code submission for HIFU reimbursement in the U.S.
View HTML
Toggle Summary EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2017
EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA , May 12-16, 2017 EDAP to Showcase Ablatherm Fusion and Sonolith i-move at AUA Booth #130 LYON, France , May 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
View HTML